AIM News and Press, AIM ImmunoTech Inc. From 12/02/22

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseas...

AIM ImmunoTech press release ( NYSE: AIM ): Q3 GAAP EPS of -$0.13 misses by $0.01 . Cash and cash equivalents of $36.7M, expected to fund operations through end of 2023. For further details see: AIM ImmunoTech GAAP EPS of -$0.13 misses by $0.01

– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 OCALA, Fla., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTec...

– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (y...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re diving into the biggest pre-market stock movers for Monday as we get ready for another week of trading! Moving shares are Trump news, earnings reports, and more. L...

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to AIM ImmunoTech's ( NYSE: AIM ) Ampligen (rintatolimod) to treat Ebola virus disease. AIM said Ampligen is its dsRNA product candidate being developed for cancers, viral diseases and dis...

Ampligen ® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system Ampligen has demonstrated positive results for the treatment of Ebola...

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Committee” or the “AS...

AIM ImmunoTech Inc. ( NYSE: AIM )  said a Delaware court announced on Monday that it denied an activist request for a preliminary injunction that sought to require the company accept his director nominations. AIM rose 6.1%. AIM ImmunoTech ( AIM ) previously an...

Corrects the Record Regarding Activist Group’s False and Misleading Statements Highlights Evidence of Group’s Scheme to Have Jorgl Serve as the “Face of the Activist” to Help Them “Get Control” Without Paying a Premium to All Sharehold...